Abstract
Background: The prevalence of obesity and related cardiovascular comorbodities is increasing rapidly. Adipokines play a major role in the pathogenesis of obesity-related inflammation and hypertension.
Aim: The aim of this study was to evaluate the serum adropin levels in obese children and to determine the relationship between adropin levels and blood pressure (BP) in the pediatric age group.
Methods: Forty obese children (mean age: 12.5±2.5 years; male/female ratio: 18/22) and 15 healthy controls (mean age: 15±3.14 years; male/female ratio: 5/15) were included in the study. Serum adropin levels, and a number of laboratory and clinical variables were compared. Ambulatory blood pressure monitoring was performed on obese subjects. Relationship between adropin levels and BP variables was examined.
Results: Serum adropin levels were significantly lower in obese subjects than in healthy controls (193.56±94 vs. 289±187 pg/mL, p=0.03). Adropin levels were correlated negatively with body mass index z-score (r=−0.56; p=0.034). There was no correlation between serum adropin levels and laboratory variables in obese subjects. Five of the patients (12.5%) were nondipper, and nine of the patients (22.5%) had hypertension. There was no significant correlation between serum adropin levels and BP variables.
Conclusion: Serum adropin levels were significantly lower in obese children; however, there was no correlation between serum adropin levels and BP variables. Further studies are needed to determine the role of adipokines on BP.
Acknowledgments
We acknowledge the support of the ARLAB (Research Laboratory) of Dokuz Eylul University Medical School, Izmir, Turkey and we want to thank Dr. Korcan Demir for his contributions.
References
1. Lakshman R, Elks CE, Ong KK. Childhood obesity. Circulation 2012;126:1770–9.10.1161/CIRCULATIONAHA.111.047738Search in Google Scholar PubMed PubMed Central
2. Pulgaron ER. Childhood obesity: a review of increased risk for physical and psychological co-morbidities. Clin Ther 2013;35:A18–32.10.1016/j.clinthera.2012.12.014Search in Google Scholar PubMed PubMed Central
3. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens 2010;19:195–200.10.1097/MNH.0b013e3283366cd0Search in Google Scholar PubMed PubMed Central
4. Urbina E, Alpert B, Flynn JT, Hayman L, Harshfield GA, et al. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assesment. Hypertension 2008;52:433–51.10.1161/HYPERTENSIONAHA.108.190329Search in Google Scholar PubMed
5. Wühl E, Witte K, Soergel M, Mehls O, Schae Fer F, et al. Distrubition of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002;20:1995–2007.10.1097/00004872-200210000-00019Search in Google Scholar PubMed
6. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014;63:250–9.10.1016/j.jjcc.2013.11.006Search in Google Scholar PubMed PubMed Central
7. Vaněčková I, Maletinská L, Behuliak M, Nagelová V, Zicha J, et al. Obesity-related hypertension: possible pathophysiological mechanism. J Endocrinol 2014;223:R63–78.10.1530/JOE-14-0368Search in Google Scholar PubMed
8. De Faria AP, Modolo R, Fontana V, Moreno H. Adipokines: novel players in resistant hypertension. J Clin Hypertens (Greenwich) 2014;16:754–9.10.1111/jch.12399Search in Google Scholar PubMed PubMed Central
9. Sabbatini AR, Fontana V, Laurent S, Moreno H. An update on the role of adipokines in arterial stiffness and hypertension. J Hypertens 2015;33:435–44.10.1097/HJH.0000000000000444Search in Google Scholar PubMed
10. Rahmouni K, Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension 2007;49:647–52.10.1161/01.HYP.0000254827.59792.b2Search in Google Scholar PubMed
11. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997;46:2040–3.10.2337/diab.46.12.2040Search in Google Scholar PubMed
12. Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008;51:534–9.10.1161/HYPERTENSIONAHA.107.103077Search in Google Scholar PubMed
13. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318–23.10.1161/01.HYP.0000129281.03801.4bSearch in Google Scholar PubMed
14. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006;47:1108–16.10.1161/01.HYP.0000222368.43759.a1Search in Google Scholar PubMed
15. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468–81.10.1016/j.cmet.2008.10.011Search in Google Scholar PubMed PubMed Central
16. Kumar KG, Zhang J, Gao S, Rossi J, Mc Guinness OP, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Siver Spring) 2012;20:1394–402.10.1038/oby.2012.31Search in Google Scholar PubMed PubMed Central
17. Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. Intern Med 2011;50:1523–7 (abstract).10.2169/internalmedicine.50.5163Search in Google Scholar PubMed
18. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 2014;190–1:46–9.10.1016/j.regpep.2014.04.001Search in Google Scholar PubMed
19. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122:185–92.10.1161/CIRCULATIONAHA.109.931782Search in Google Scholar PubMed
20. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, et al. Plasma adropin levels predict endothelial dysfuction like flow-mediated dilatation in patients type 2 diabetes mellitus. J Investig Med 2013;61:1161–4.10.2310/JIM.0000000000000003Search in Google Scholar PubMed
21. Wu L, Fang J, Chen L, Zhao Z, Luo Y, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2014:52:751–8.10.1515/cclm-2013-0844Search in Google Scholar
22. Sayin O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver diease. J Pediatr Endocrinol Metab 2014;27:479–84.10.1515/jpem-2013-0296Search in Google Scholar
23. Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypas surgery in humans. J Clin Endocrinol Metab 2012;97:3783–91.10.1210/jc.2012-2194Search in Google Scholar
24. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan HL, et al. Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 2013;163:1122–6.10.1016/j.jpeds.2013.05.040Search in Google Scholar
25. Strauss RS. Childhood obesity. Pediatr Clin North Am 2002;49:175–201.10.1016/S0031-3955(03)00114-7Search in Google Scholar
26. Atabek ME, Pirgon O, Kurtoğlu S. Assessment of abnormal glucose homeostatis and insulin resistance in Turkish obese children and adolescents. Diabetes Obes Metab 2007;9: 304–10.10.1111/j.1463-1326.2006.00601.xSearch in Google Scholar PubMed
27. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, Siani P, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 206;16:279–84.10.1016/j.numecd.2005.12.007Search in Google Scholar PubMed
28. Flynn JT, Daniel SR, Hayman LL, Maahs DM, McCrindle BW, et al. Uptade: ambulatory blood pressure monitoring in children ad adolescents. Hypertension 2014;63:1116–35.10.1161/HYP.0000000000000007Search in Google Scholar PubMed PubMed Central
29. Çelik A, Balın M, Kobat MA, Erdem K, Baydas A, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 2013;31:174–8.10.1111/1755-5922.12025Search in Google Scholar PubMed
30. St-Onge MP, Shechter A, Shlisky J, Tam C, Gao S, et al. Fasting plasma adropin concentrations correlate with fat consumtion in human females. Obesity (Silver Spring) 2014;22: 1056–63.10.1002/oby.20631Search in Google Scholar PubMed PubMed Central
31. Gonzalez M, Lind L, Soderberg S. Leptin and endothelial function in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2013;228:485–90.10.1016/j.atherosclerosis.2013.03.018Search in Google Scholar PubMed
32. Sabbatini AR, Faria AP, Barbaro NR, Gordo WM, Modolo RG, et al. Deregulation of adipokines related to target organ damage on resistant hypertension. J Hum Hypertens 2014; 28:388–92.10.1038/jhh.2013.118Search in Google Scholar PubMed
33. Sen H, Bakiler AR, Aydoğdu SA, Unuvar T, Yenisey C, et al. The mechanical properties and stiffness of aorta in obese children. Turk J Pediatr 2013;55:309–14.Search in Google Scholar
34. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologica 2003;46:1543–9.10.1007/s00125-003-1224-3Search in Google Scholar PubMed
©2015 by De Gruyter
